SCHEMBL29336678

SCHEMBL29336678

COC(=O)c1cccc(Oc2ccc3[nH]ccc3c2CO)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MTNR1A P48039 1/20 0.44
▸ MTNR1B P49286 1/20 0.44
▸ L3MBTL1 Q9Y468 2/20 0.43
▸ GPR84 Q9NQS5 1/20 0.41
▸ RHEB Q15382 1/20 0.41
▸ USP2 O75604 1/20 0.41
▸ CYP4F2 P78329 2/20 0.40
▸ CYP4A11 Q02928 2/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ MET P08581 1/20 0.40
▸ ALK Q9UM73 1/20 0.40
▸ ATM Q13315 1/20 0.40
▸ TP53 P04637 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ CDK8 P49336 1/20 0.39
▸ TUBB4A P04350 1/20 0.39
▸ TUBB P07437 1/20 0.39
▸ TUBA3C P0DPH7 1/20 0.39
▸ TUBA1B P68363 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31108617 0.86 L3MBTL1 (0.44) L3MBTL1GPR84RHEBUSP2MET
SCHEMBL30285551 0.86 L3MBTL1 (0.44) MTNR1AMTNR1BL3MBTL1GPR84RHEB
SCHEMBL29337712 0.86 L3MBTL1 (0.44) MTNR1AMTNR1BL3MBTL1GPR84RHEB
SCHEMBL29337702 0.83 USP2 (0.43) L3MBTL1GPR84RHEBUSP2MET
SCHEMBL29237351 0.81 F10 (0.46) RHEB
SCHEMBL30938228 0.81 F10 (0.46) RHEB
SCHEMBL29338295 0.78 KDM4E (0.40) MTNR1AMTNR1BL3MBTL1RHEBUSP2
SCHEMBL30967802 0.78 EPAS1 (0.49) RHEB
SCHEMBL29237661 0.78 EPAS1 (0.49) RHEB
SCHEMBL30285558 0.77 TUBB4A (0.39) MTNR1AMTNR1BL3MBTL1RHEBUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239784-A1 INDOLE COMPOUNDS AND METHODS OF USE GENZYME CORPORATION 2024-07-18 — — US disclosed
US-20240239784-A1 INDOLE COMPOUNDS AND METHODS OF USE GENZYME CORPORATION 2024-07-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239784-A1 INDOLE COMPOUNDS AND METHODS OF USE CFTR, INMT, IDO1 MTNR1A 308/4885MTNR1B 101/4885L3MBTL1 3265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback